Company profile
NeurAxis, Inc.
AMEX: NRXS · Healthcare · Biotechnology
#730 of 1,418 Healthcare companies by revenue73rd-percentile growth
EA Score
45DFH 44DQ 36GM 71SS 37
v0.1 · 65/100 weight · provisional
↑ Altman-Z, revenue growth (YoY) · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$4.3M
Rev growth YoY (TTM)
+45.9%
Net income (FY)
-$7.8M
Employees
24
as of 2026-08-18
Market cap
$78.7M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.6M$3.6M2025
Net income-$7.8M-$7.8M2025
Operating income-$7.8M-$7.8M2025
Total assets$6.4M$6.4M2025
Liabilities$3.0M$3.0M2025
Equity$3.4M$3.4M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is NeurAxis, Inc.’s revenue?
NeurAxis, Inc. booked $3.6M in FY2025 revenue, growing 33% year over year — faster than most Healthcare companies we track, at a -218.5% net margin.
Peers · Healthcare
EVIO, Inc.——Oncologix Tech Inc.——Cibus, Inc.43DRed Light Holland Corp.——Marker Therapeutics, Inc.36DRevitalist Lifestyle and Wellness Ltd.——Neighbors
Hamilton →Key facts
CEOBrian Carrico
SectorHealthcare
IndustryBiotechnology
HeadquartersCarmel, IN
ExchangeAMEX: NRXS
Employees24
IPO date2023-08-09
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.